JP5701760B2 - 炭疽菌ワクチン製剤とその用途 - Google Patents

炭疽菌ワクチン製剤とその用途 Download PDF

Info

Publication number
JP5701760B2
JP5701760B2 JP2011529634A JP2011529634A JP5701760B2 JP 5701760 B2 JP5701760 B2 JP 5701760B2 JP 2011529634 A JP2011529634 A JP 2011529634A JP 2011529634 A JP2011529634 A JP 2011529634A JP 5701760 B2 JP5701760 B2 JP 5701760B2
Authority
JP
Japan
Prior art keywords
phosphate
rpa
formulation
anthrax
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011529634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012504589A5 (enExample
JP2012504589A (ja
Inventor
ワトキンソン，アラン
ウッドハウス，デービッド
ウィルソン，ロバート
Original Assignee
ファーマシーネ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマシーネ，インコーポレイテッド filed Critical ファーマシーネ，インコーポレイテッド
Publication of JP2012504589A publication Critical patent/JP2012504589A/ja
Publication of JP2012504589A5 publication Critical patent/JP2012504589A5/ja
Application granted granted Critical
Publication of JP5701760B2 publication Critical patent/JP5701760B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2011529634A 2008-10-02 2009-10-02 炭疽菌ワクチン製剤とその用途 Expired - Fee Related JP5701760B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19496708P 2008-10-02 2008-10-02
US61/194,967 2008-10-02
PCT/GB2009/051293 WO2010038076A1 (en) 2008-10-02 2009-10-02 Anthrax vaccine formulation and uses thereof

Publications (3)

Publication Number Publication Date
JP2012504589A JP2012504589A (ja) 2012-02-23
JP2012504589A5 JP2012504589A5 (enExample) 2012-11-22
JP5701760B2 true JP5701760B2 (ja) 2015-04-15

Family

ID=41292568

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011529634A Expired - Fee Related JP5701760B2 (ja) 2008-10-02 2009-10-02 炭疽菌ワクチン製剤とその用途

Country Status (7)

Country Link
US (1) US9616117B2 (enExample)
EP (1) EP2344188B1 (enExample)
JP (1) JP5701760B2 (enExample)
AU (1) AU2009299615B2 (enExample)
CA (1) CA2738621C (enExample)
IL (1) IL212118A (enExample)
WO (1) WO2010038076A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009299615B2 (en) 2008-10-02 2015-07-16 Pharmathene Inc. Anthrax vaccine formulation and uses thereof
WO2014134187A1 (en) * 2013-02-26 2014-09-04 The Regents Of The University Of California Compositions and methods for the treatment of cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK140815B (da) * 1975-06-10 1979-11-19 Weeke Bengt Fremgangsmåde til påvisning eller bestemmelse af antistoffer i legemsvæsker ved hjælp af kendte antigener eller til bestemmelse af antigener ved hjælp af kendte antistoffer fra legemsvæsker samt et middel til anvendelse ved udøvelse af fremgangsmåden.
DE2632478A1 (de) 1975-07-23 1977-02-24 Coulter Electronics Verfahren zur erfassung und trennung von antigenen und antikoerperchen im blut und in anderen proben
US4486530A (en) * 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
ATE68524T1 (de) * 1985-07-09 1991-11-15 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
US5690942A (en) 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9618107D0 (en) 1996-08-30 1996-10-09 Secr Defence Vaccine production
US20020120228A1 (en) * 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
KR20030020294A (ko) 2000-06-08 2003-03-08 파우더젝트 백신, 인코포레이티드 분말 조성물
GB0016702D0 (en) 2000-07-08 2000-08-23 Secr Defence Brit Expression system
WO2002100340A2 (en) 2001-06-08 2002-12-19 Avant Immunotherapeutics, Inc. Improved vaccination against anthrax
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0126266D0 (en) * 2001-11-01 2002-01-02 Microbiological Res Authority Anthrax antigenic compositions
UA80809C2 (en) 2001-11-05 2007-11-12 Process for preparation of protective antigen protein of anthracis with e.coli
US7888490B2 (en) 2001-12-05 2011-02-15 Centre of Biotechnology Jawaharlal Nehru University Process for the preparation of non-toxic anthrax vaccine
ATE503491T1 (de) 2003-02-13 2011-04-15 Becton Dickinson Co Verbesserte anthraximpfstoffe und abgabeverfahren
EP1755677A4 (en) 2004-06-14 2009-11-25 Medimmune Vaccines Inc HIGH-PRESSURE SPRAY DRYING OF BIOACTIVE MATERIALS
US7355027B2 (en) 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
JP2008514644A (ja) 2004-09-28 2008-05-08 アルザ コーポレイション ミョウバンアジュバント免疫活性剤の安定化
GB0525213D0 (en) 2005-12-12 2006-01-18 Secr Defence Vaccine
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
GB0607462D0 (en) 2006-04-13 2006-05-24 Avecia Ltd Assay
JP2010502747A (ja) 2006-09-08 2010-01-28 ベクトン・ディキンソン・アンド・カンパニー ミョウバン吸着ワクチンの安定粉末製剤
EP1972347A1 (en) 2007-03-19 2008-09-24 Becton, Dickinson and Company, Wagner, Jaconda Stable vaccine powder formulations
WO2008152654A1 (en) 2007-06-11 2008-12-18 Panacea Biotec Limited Anthrax fusion proteins, compositions and uses thereof
GB0801122D0 (en) * 2008-01-22 2008-02-27 Avecia Biolog Ltd Vaccine composition
AU2009299615B2 (en) 2008-10-02 2015-07-16 Pharmathene Inc. Anthrax vaccine formulation and uses thereof
WO2010084298A1 (en) 2009-01-22 2010-07-29 Pharmathene Uk Limited Stable vaccine compositions and methods of use

Also Published As

Publication number Publication date
WO2010038076A1 (en) 2010-04-08
CA2738621A1 (en) 2010-04-08
US20110236425A1 (en) 2011-09-29
IL212118A0 (en) 2011-07-31
EP2344188B1 (en) 2017-02-15
AU2009299615A1 (en) 2010-04-08
JP2012504589A (ja) 2012-02-23
IL212118A (en) 2017-03-30
EP2344188A1 (en) 2011-07-20
AU2009299615B2 (en) 2015-07-16
CA2738621C (en) 2017-01-31
US9616117B2 (en) 2017-04-11

Similar Documents

Publication Publication Date Title
Ambühl et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity
JP2020203889A (ja) 抗体製剤
TWI725973B (zh) 抗-ｃｇｒｐ抗體調配物
JP5956974B2 (ja) パピローマウイルスワクチン組成物
AU2007248628B2 (en) CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
CN116023510B (zh) 双佐剂重组带状疱疹疫苗
CN103998056B (zh) 用于接种抗金黄色葡萄球菌疫苗的方法和组合物
EA014025B1 (ru) Композиции антитела против cd3
Wang et al. A supramolecular protein chaperone for vaccine delivery
JP2013543501A5 (enExample)
JP2008528612A5 (enExample)
JP5745577B2 (ja) Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用
JP2003518507A5 (enExample)
JP2016537416A (ja) 脳マラリアを治療するためのアンギオポエチンに基づいた介入
JP2012504589A (ja) 炭疽菌ワクチン製剤とその用途
Azegami et al. Vaccine Development against the Renin‐Angiotensin System for the Treatment of Hypertension
WO2024148364A1 (en) Intertumoral and intratumoral delivery of cytokines using mesoporous silica rods as an immunomodulating system
CN118403155A (zh) 用于治疗脊髓损伤和疼痛的抗反义导向分子a（rgma）拮抗性抗体
WO2021017365A1 (zh) Cra4S1基因及其编码的蛋白和应用
RU2404794C2 (ru) Вагинальные суппозитории для лечения рака шейки матки
JP6559898B2 (ja) スクアレンを含む両親媒性ポリアミノ酸高分子に基づくワクチンの免疫補助剤組成物
CN120390752A (zh) 靶向具有半胱天冬酶激活和募集结构域(asc)的凋亡相关斑点样蛋白的组合物及使用方法
JP6692755B2 (ja) アルツハイマー病（ａｄ）の処置および予防
JP5960064B2 (ja) ヒトプロガストリンペプチドに対する免疫原性組成物
CN121466278A (zh) 抗tnfsf8肽疫苗及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140313

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140410

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141024

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150218

R150 Certificate of patent or registration of utility model

Ref document number: 5701760

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees